These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Antisense applications for biological control. Pan WH; Clawson GA J Cell Biochem; 2006 May; 98(1):14-35. PubMed ID: 16440307 [TBL] [Abstract][Full Text] [Related]
5. Filling the gap in LNA antisense oligo gapmers: the effects of unlocked nucleic acid (UNA) and 4'-C-hydroxymethyl-DNA modifications on RNase H recruitment and efficacy of an LNA gapmer. Fluiter K; Mook OR; Vreijling J; Langkjaer N; Højland T; Wengel J; Baas F Mol Biosyst; 2009 Aug; 5(8):838-43. PubMed ID: 19603119 [TBL] [Abstract][Full Text] [Related]
6. Inhibition of HIV-1 replication by a new type of circular dumbbell RNA/DNA chimeric oligonucleotides. Park WS; Miyano-Kurosaki N; Abe T; Takai K; Yamamoto N; Takaku H Biochem Biophys Res Commun; 2000 Apr; 270(3):953-60. PubMed ID: 10772932 [TBL] [Abstract][Full Text] [Related]
8. Development of antisense oligodeoxynucleotides for transplantation. Stepkowski SM Curr Opin Mol Ther; 2000 Jun; 2(3):304-17. PubMed ID: 11249625 [TBL] [Abstract][Full Text] [Related]
9. Building oligonucleotide therapeutics using non-natural chemistries. Wilson C; Keefe AD Curr Opin Chem Biol; 2006 Dec; 10(6):607-14. PubMed ID: 17049298 [TBL] [Abstract][Full Text] [Related]
10. Cytokines and therapeutic oligonucleotides. Hartmann G; Bidlingmaier M; Eigler A; Hacker U; Endres S Cytokines Cell Mol Ther; 1997 Dec; 3(4):247-56. PubMed ID: 9740353 [TBL] [Abstract][Full Text] [Related]
11. Peptide-mediated cellular delivery of antisense oligonucleotides and their analogues. Gait MJ Cell Mol Life Sci; 2003 May; 60(5):844-53. PubMed ID: 12827274 [TBL] [Abstract][Full Text] [Related]
12. Fine tuning of electrostatics around the internucleotidic phosphate through incorporation of modified 2',4'-carbocyclic-LNAs and -ENAs leads to significant modulation of antisense properties. Zhou C; Liu Y; Andaloussi M; Badgujar N; Plashkevych O; Chattopadhyaya J J Org Chem; 2009 Jan; 74(1):118-34. PubMed ID: 19055352 [TBL] [Abstract][Full Text] [Related]
13. Antisense treatments for biothreat agents. Warfield KL; Panchal RG; Aman MJ; Bavari S Curr Opin Mol Ther; 2006 Apr; 8(2):93-103. PubMed ID: 16610760 [TBL] [Abstract][Full Text] [Related]
14. Sugar boost: when ribose modifications improve oligonucleotide performance. Faria M; Ulrich H Curr Opin Mol Ther; 2008 Apr; 10(2):168-75. PubMed ID: 18386229 [TBL] [Abstract][Full Text] [Related]
15. RNAi: a novel antisense technology and its therapeutic potential. Dallas A; Vlassov AV Med Sci Monit; 2006 Apr; 12(4):RA67-74. PubMed ID: 16572063 [TBL] [Abstract][Full Text] [Related]
17. Antisense oligonucleotides and prevention of tumor growth: a different approach and proposal for a new method. Yildiz D; Oztas H; Hilal Ates B Med Hypotheses; 2005; 64(2):328-32. PubMed ID: 15607566 [TBL] [Abstract][Full Text] [Related]
18. Hybrid oligonucleotides: synthesis, biophysical properties, stability studies, and biological activity. Yu D; Iyer RP; Shaw DR; Lisziewicz J; Li Y; Jiang Z; Roskey A; Agrawal S Bioorg Med Chem; 1996 Oct; 4(10):1685-92. PubMed ID: 8931938 [TBL] [Abstract][Full Text] [Related]